A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

Exclusion Criteria

• •1. Subject plans to receive gene therapy or participate in another interventional study for Pompe disease.
• •2. Subject, if female, is pregnant or breastfeeding.
• •3. Subject, whether male or female, is planning to conceive a child during the study.
• •4. Subject had a hypersensitivity to any of the excipients in cipaglucosidase alfa or miglustat, or had a medical condition or any other extenuating circumstance that may have, in the opinion of the investigator or medical monitor, posed an undue safety risk to the subject or may have compromised his/her ability to comply with or adversely impacted protocol requirements.